Efficacy and safety of biologic treatments in Familial Mediterranean Fever

American Journal of the Medical Sciences

Volumn 346, Issue 2, 2013, Pages 137-141

  Akgul, Ozgur ^a   Kilic, Erkan ^a   Kilic, Gamze ^a   Ozgocmen, Salih ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Adalimumab; Anakinra; Canakinumab; Etanercept; Familial Mediterranean Fever; Infliximab

Indexed keywords

ADALIMUMAB; BIOLOGIC FACTORS AND AGENTS ACTING ON THE IMMUNE SYSTEM; CANAKINUMAB; COLCHICINE; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANKYLOSING SPONDYLITIS; CASE REPORT; CASE STUDY; CINCA SYNDROME; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FAMILIAL MEDITERRANEAN FEVER; HUMAN; JUVENILE; NEUROMUSCULAR DISEASE; NEUTROPENIA; PSORIATIC ARTHRITIS; QUANTITATIVE ANALYSIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84880817775     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318277083b     Document Type: Review

References (55)

1. Ryan JG, Goldbach-Mansky R. The spectrum of autoinflammatory diseases: recent bench to bedside observations. Curr Opin Rheumatol 2008;20:66-75.
2. Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 2011;7:105-12.
3. Fonnesu C, Cerquaglia C, Giovinale M, et al. Familial Mediterranean Fever: a review for clinical management. Joint Bone Spine 2009;76:227-33.
4. Akkoc N, Gul A. Familial Mediterranean fever and seronegative arthritis. Curr Rheumatol Rep 2011;13:388-94.
5. Kasifoglu T, Calisir C, Cansu DU, et al. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol 2009;28:41-6.
6. Ben-Chetrit E, Touitou I. Familial Mediterranean Fever in the world. Arthritis Rheum 2009;61:1447-53.
7. Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007;119:e474-83.
8. Sayarlioglu H, Erkoc R, Sayarlioglu M, et al. Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases. Rheumatol Int 2006;27:197-9.
9. Bakkaloglu SA, Aksu T, Goker B, et al. Sulphasalazine treatment in protracted familial Mediterranean fever arthritis. Eur J Pediatr 2009;168: 1017-9.
10. Gattringer R, Lagler H, Gattringer KB, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 2007;37:912-4.
11. Calligaris L, Marchetti F, Tommasini A, et al. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 2008;167:695-6.
12. Bodur H, Seckin U, Eser F, et al. Coexistence of Familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy. Rheumatol Int 2008;29:107-10.
13. Metyas S, Arkfeld DG, Forrester DM, et al. Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol 2004;10:134-7.
14. Daysal S, Akcil G, Goker B, et al. Infliximab therapy in a patient with Familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum 2005;53:146-7.
15. Yuksel S, Yalcinkaya F, Acar B, et al. Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 2006;45:1307-8.
16. Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol 2006;24:435-7.
17. Ozgocmen S, Ozcakar L, Ardicoglu O, et al. Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol 2006;25:83-7.
18. Seyahi E, Ozdogan H, Celik S, et al. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 2006;24:S99-103.
19. Mor A, Pillinger MH, Kishimoto M, et al. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol 2007;13:38-40.
20. Brik R, Gepstein V, Shahar E, et al. Tumor necrosis factor blockade in the management of children with orphan diseases. Clin Rheumatol 2007;26:1783-5.
21. Kaya S, Kaptanoglu E, Elden H, et al. Coexistence of familial Mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept. Intern Med 2010;49:619-22.
22. Nakamura A, Matsuda M, Tazawa K, et al. Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever. Intern Med 2007;46:1247-9.
23. Erten S, Erten SF, Altunoglu A. Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial Mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF. Rheumatol Int 2012;32:1095-7.
24. Zihni FY, Kalfa M, Ocakci PT, et al. Coexistence of Takayasu's arteritis with familial Mediterranean fever. Rheumatol Int 2012;32:1675-8.
25. Bilgen SA, Kilic L, Akdogan A, et al. Effects of anti-tumor necrosis factor agents for Familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol 2011;17:358-62.
26. Belkhir R, Moulonguet-Doleris L, Hachulla E, et al. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007;146: 825-6.
27. Kuijk LM, Govers AM, Frenkel J, et al. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 2007;66:1545-6.
28. Mitroulis I, Papadopoulos VP, Konstantinidis T, et al. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med 2008;66:489-91.
29. Roldan R, Ruiz AM, Miranda MD, et al. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 2008;75:504-5.
30. Hennig S, Bayegan K, Uffmann M, et al. Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra-case report and review. Rheumatol Int 2010.
31. Moser C, Pohl G, Haslinger I, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant 2009;24:676-8.
32. Alpay N, Sumnu A, Caliskan Y, et al. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int 2012;32:3277-9.
33. Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease. Clin Rheumatol 2010;29:209-10.
34. Petropoulou AD, Robin M, Socie G, et al. Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra. Transplantation 2010;90:102-3.
35. Meinzer U, Quartier P, Alexandra JF, et al. Interleukin-1 targeting drugs in Familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011;41:265-71.
36. Ozen S, Bilginer Y, Aktay Ayaz N, et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011;38:516-8.
37. Mitroulis I, Skendros P, Oikonomou A, et al. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis 2011;70:1347-8.
38. Stankovic Stojanovic K, Delmas Y, Urena Torres P, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 2012;27:1898-900.
39. Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology (Oxford) 2012;51:1041.
40. Ozgocmen S, Akgul O. Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature. Mod Rheumatol 2011;21:684-90.
41. Chae JJ, Cho YH, Lee GS, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 2011;34:755-68.
42. Kiraz S, Ertenli I, Arici M, et al. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol 1998;16:721-4.
43. Limatola C, Barabino B, Nista A, et al. Interleukin 1-beta-induced protein kinase C-zeta activation is mimicked by exogenous phospholipase D. Biochem J 1997;321(pt 2):497-501.
44. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
45. Butler DM, Maini RN, Feldmann M, et al. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995;6:225-30.
46. Probert L, Plows D, Kontogeorgos G, et al. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 1995;25:1794-7.
47. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
48. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000;7:64-9.
49. Dember LM, Hawkins PN, Hazenberg BP, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356: 2349-60.
50. Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005;118:552-6.
51. Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24.
52. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009;68:25-32.
53. Heldmann F, Dybowski F, Saracbasi-Zender E, et al. Update on biologic therapy in the management of axial spondyloarthritis. Curr Rheumatol Rep 2010;12:325-31.
54. Ozturk MA, Kanbay M, Kasapoglu B, et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol 2011;29:S77-86.
55. Ho PM, Peterson PN, Masoudi FA. Evaluating the evidence: is there a rigid hierarchy? Circulation 2008;118:1675-84.